Centre Hospitalier de Mouscron, Service de diabétologie et endocrinologie, Mouscron, Belgium.
Cliniques Universitaires Saint-Luc, Service d'Endocrinologie et Nutrition, Brussels, Belgium.
J Diabetes Complications. 2023 Feb;37(2):108385. doi: 10.1016/j.jdiacomp.2022.108385. Epub 2022 Dec 26.
There is limited real-life data demonstrating that hypo-/hyperglycemic alarms added to continuous glucose monitoring (CGM) improve metabolic control in adults with type 1 diabetes (T1D). We evaluated the usefulness of switching from a flash or intermittent-scanned continuous glucose monitoring (is-CGM) device without low or higher glucose alarms to a is-CGM device with alarms to prevent hypoglycemia in adults with T1D.
Individuals with T1D and fearful of hypoglycemia, prone to hypoglycemia unawareness, and/or experiencing severe hypoglycemia while using is-CGM Free Style Libre 1 (FSL1) were switched to FSL2 with individually-programmable low glucose alarms. The primary endpoint was the changes in % time below range (TBR%) <70 mg/dl [3.9 mmol/l] and <54 mg/dl [3.0 mmol/l] after 12 weeks on FSL2 compared with FSL1. Secondary endpoints were changes in % time in range (TIR% 70-180 mg/dl [3.9-10.0 mmol/l]), % time above range (TAR%) >180 [10.0 mmol/l], mean interstitial glucose, glycemic management indicator (GMI), interstitial glucose coefficient of variation (CV%), hemoglobin A1c, and sensor's scans/day.
We included 108 individuals (57.4 % men), aged 58.2 ± 17.3 [95 % CI: 55.0 to 61.5] years, with mean diabetes duration 25 ± 14.6 [95 % CI: 22.1 to 27.7] years. Among individuals, 40 (37.0 %) had hypoglycemia awareness with Clarke's score ≥4 and 19 (17.5 %) had a history of severe hypoglycemia. The median low glucose alarm threshold was 70 [IQR: 65-70] mg/dl (3.9 [IQR: 3.6-3.9] mmol/L). By comparison of first 12 weeks on FSL2 vs. last 12 weeks on FSL1, TBR% <70 mg/dl decreased from 4.5 ± 4.4 to 2.3 ± 2.8 % (p < 0.001), TBR% <54 mg/dl decreased from 1.4 ± 2.2 to 0.3 ± 0.9 % (p < 0.001). TIR% was not significantly different (51.5 ± 14.9 vs. 52.9 ± 16 % (p = 0.13)), nor was TAR% (43.8 ± 16.2 vs. 44.7 ± 16.5 % (p = 0.5)). CV% decreased from 39.4 ± 6.9 to 37.9 ± 6.1 % (p < 0.001). Those at risk for hypoglycemia (TBR >4 % and >1 %, respectively, at baseline) showed a significant decrease in the incidence of hypoglycemia <70 and <54 mg/dl (p < 0.0001). Patients' satisfaction with hypoglycemia alarms was high, since all individuals opted to pursue using individual alarm beyond the study period.
Switching from FSL1 to FSL2 with low glucose alarms reduced the frequency of hypoglycemia in middle-age adults with T1D, particularly in those who were prone to hypoglycemia awareness or severe hypoglycemia.
在成人 1 型糖尿病(T1D)患者中,低血糖/高血糖报警附加于连续血糖监测(CGM)以改善代谢控制的真实生活数据有限。我们评估了从没有低血糖或高血糖报警的闪光或间歇扫描连续血糖监测(is-CGM)设备切换到具有报警功能的 is-CGM 设备以预防 T1D 成人低血糖的实用性。
使用 is-CGM Free Style Libre 1(FSL1)时有低血糖恐惧、低血糖感知障碍倾向和/或发生严重低血糖的 T1D 患者切换到具有个体编程低血糖报警的 FSL2。主要终点是与 FSL1 相比,在 FSL2 上的第 12 周时,<70mg/dl [3.9mmol/l]和<54mg/dl [3.0mmol/l]的时间百分比(TBR%)变化。次要终点是时间百分比(TIR% 70-180mg/dl [3.9-10.0mmol/l])、时间百分比(TAR% >180 [10.0mmol/l])、平均间质葡萄糖、血糖管理指标(GMI)、间质葡萄糖变异系数(CV%)、糖化血红蛋白和传感器扫描/天的变化。
我们纳入了 108 名年龄为 58.2±17.3 岁(95%置信区间:55.0 至 61.5)的个体,其中男性占 57.4%,糖尿病病程平均为 25±14.6 年(95%置信区间:22.1 至 27.7)。在这些患者中,40 名(37.0%)有 Clarke 评分≥4 的低血糖感知障碍,19 名(17.5%)有严重低血糖病史。低血糖报警阈值的中位数为 70[IQR:65-70]mg/dl(3.9[IQR:3.6-3.9]mmol/L)。与 FSL1 的前 12 周相比,FSL2 的第 12 周时,<70mg/dl 的 TBR%从 4.5±4.4%降至 2.3±2.8%(p<0.001),<54mg/dl 的 TBR%从 1.4±2.2%降至 0.3±0.9%(p<0.001)。TIR%无显著差异(51.5±14.9%与 52.9±16%(p=0.13)),TAR%也无显著差异(43.8±16.2%与 44.7±16.5%(p=0.5))。CV%从 39.4±6.9%降至 37.9±6.1%(p<0.001)。有低血糖风险的患者(基线时分别为 TBR>4%和>1%),<70 和<54mg/dl 的低血糖发生率显著下降(p<0.0001)。患者对低血糖报警的满意度很高,因为所有患者都选择在研究结束后继续使用个体报警。
从 FSL1 切换到具有低血糖报警的 FSL2 可降低 T1D 成年患者低血糖的发生频率,尤其是在有低血糖感知障碍或严重低血糖病史的患者中。